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In the production of monoclonal antibodies, a rapid, sensitive, accurate assay is needed for the critical 
step of screening. We report the modification of an assay using viable whole cells for screening hybridoma 
supernatants. The modified assay uses fluorescent second antibodies for detection and has been adapted to 
an instrument capable of automating a number  of assay steps. The modified assay is compared to a dot 
radioimmunoassay developed and used in our laboratory. The fluorescence assay is highly sensitive but 
shows more background effect, especially in samples with high protein content, such as ascites. The 
automated fluorescence assay is very rapid, capable of completing an assay in less than 90 min, and can be 
performed with minimal operator involvement. The assay was performed successfully with several different 
antibodies and cell types. This screening procedure should be especially useful for laboratories with large 
numbers of fusions to evaluate. 
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Introduction 
One of the most time-consuming and labor-in- 
tensive steps in the production of monoclonal 
antibodies is the screening. Screening is a critical 
step in the development of monoclonal antibodies 
of desired specificity, because screening results are 
used to determine which cells will be subcloned 
and saved. Time is also a limiting factor because 
of cell growth while waiting for results. Therefore, 
the assay chosen must be accurate, fast, sensitive, 
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inexpensive, and capable of handling many sam- 
ples at once (Goding, 1980; Eshhar, 1985). 
Many techniques have been developed for 
screening monoclonal antibodies, such as ELISAs, 
radioimmunoassays, and fluorescent assays (e.g., 
Goding, 1980; Howard et al., 1980; Kennett, 1980; 
Glassy et al., 1983; Furst and Mahowald, 1984; 
Stya et al., 1984; Eshhar, 1985; Hough et al., 
1986; Okumura et al., 1986; and others). For 
production of antibodies likely to be useful for 
tumor imaging and therapy, target antigens must 
be accessible on the tumor cell surface in situ. For 
this purpose, we previously developed an assay 
that detected antigens on the surface of whole live 
cells (Stya et al., 1984). We here report the devel- 
opment  and use of a fluorescent assay that uses 
whole live cells for screening hybridomas in an 
instrument capable of automating a number of 
assay steps. Automation greatly reduces the labor 
0022-1759/87/$03.50 ~ 1987 Elsevier Science Publishers B.V. (Biomedical Division) 
86 
and time involved in screening hybridomas. This 
report describes our optimization of the technique 
and compares it to the 'dot radioimmunobinding' 
(DRIB) assay previously described (Stya et al., 
1984). 
Materials and methods 
Antibodies 
The antibodies used in these experiments in- 
clude 5G6.4, a murine monoclonal IgG antibody 
prepared in this laboratory that has specificity for 
ovarian cancer (Wahl et al., 1986). An anti- 
melanoma antibody, 225.28S (IgG2a) has been 
previously described (Wilson et al., 1983). 6g10 is 
directed against an antigen on small cell carcinoma 
of the lung and was prepared in this laboratory 
(Stya, unpublished). Purified antibodies were pre- 
pared from ascites using chromatography (staph- 
ylococcal protein A (SPA) for IgG2a and DEAE 
for IgG1 (Ey et al., 1970; Goding, 1980, respec- 
tively)). Purified UPC-10 was purchased (Organon 
Teknika Corp., Irving, TX). Affinity-purified sec- 
ond antibodies, rabbit anti-mouse IgG, and fluo- 
rescein-isothiocyanate (FITC)-conjugated goat 
anti-mouse IgG, A and M, were purchased (Cap- 
pel, Malvern, PA; Kirkegaard and Perry, 
Gaithersburg, MD). 
Cell Lines 
The cell lines used include HTB 77, human 
ovarian cancer, the human melanoma lines HTB 
66 and 63, and human small cell carcinoma of the 
lung NCI 69; all cell lines were obtained from 
ATCC, Rockville, MD. Viability was evaluated by 
staining with fluorescein diacetate, as previously 
described (Rotman and Papermaster, 1966; Jones 
and Senft, 1985). 
Assays 
The dot-radioimmunobinding assay (DRIB) 
was performed as previously described (Stya et al., 
1984), with slight modifications. Briefly, the assay 
is performed as follows: 96-well plates with mem- 
brane bottoms (Millipore) are blocked with DRIB 
buffer  (2% BSA, 1% E D T A  in 0.01 M 
phosphate-buffered saline (PBS), pH 7.2, over- 
night at 4 ° C  to prevent non-specific sticking of 
antibody and 125I-labeled staphylococcal protein 
A (SPA) to the membrane or plate. Viable tissue 
cultured target cells, washed three times or more 
with PBS, are resuspended in DRIB buffer at a 
concentration of 10 7 cells/ml; 3/~1 of this suspen- 
sion is dotted onto the center of each test mem- 
brane (well). The antibody or supernatant to be 
tested is added to the well and allowed to incubate 
for 15 rain at room temperature. The well is 
washed four times; each wash occurs by filling the 
well (>  300/~1) with DRIB buffer, then emptying 
the well using the vacuum manifold designed for 
the plates (Millipore, Bedford, MA). In a modifi- 
cation of the previously described technique, after 
the fourth wash, 50 /~1 of rabbit anti-mouse IgG 
diluted 1/100 in DRIB buffer, is added to each 
test well. This reagent allows any subclass of 
mouse immunoglobulin binding to target cells to 
be detected using the ~25I-labeled SpA used as a 
developing reagent. After 15 min of incubation at 
room temperature, the plate is then washed four 
times and 50 /~1 of 125I-labeled SpA (NEN Re- 
search Products, Boston, MA) diluted to 50000 
counts /ml ,  are added to each well. The plate is 
incubated for 15 min at room temperature, washed 
6-8  times, and allowed to dry. The assay is 
evaluated quantitatively by autoradiographic ex- 
posure of XAR film (Kodak, Rochester, NY) for 
6 12 h with development in an RPXOMAT devel- 
oper, and quantitatively by punching out individ- 
ual wells and counting the membrane in a gamma 
counter. 
The whole-cell fluorescent immunoassay was 
performed using the screen machine (Pandex, 
Mundelein, IL). This computer-controlled instru- 
ment uses a special 96-well membrane-bottomed 
plate that is filled and washed automatically by a 
series of pipets within the machine. The wells are 
emptied by suction through the bottom of the 
plates using a vacuum line within the machine. 
The instrument is also capable of automatically 
adding reagents and following a user controlled 
protocol to wash the wells of the plates. The 
instrument has a specially designed fluorimeter 
capable of exciting and reading at several wave- 
lengths (we used 489/515 nm). In this assay, 20/xl 
of a 1% solution of BSA-coated polystyrene beads, 
3 ktm in diameter, were added automatically to the 
wells of the plate by the instrument. Then, 
20000-50000 washed viable tissue cultured cells 
were dotted onto the wells in a small volume; 50 
/xl of antibody or hybridoma supernatant are ad- 
ded. These latter two steps were usually performed 
manually in this laboratory to reduce the number  
o f  cells required for assay. The instrument is capa- 
ble of adding any reagent that is added to a 
number  of wells but the reservoir has a relatively 
large (2 ml) deadspace. This mixture was in- 
cubated for 15 min at room temperature within 
the instrument. The wells were then subject to a 
vacuum through a small port on the side of the 
plate. This process removes the liquid material in 
the well. The wells were then washed with PBS (50 
/~l/well) by the instrument. The wash material 
was removed by vacuum and 50 btl of FITC-con- 
jugated goat or rabbit  anti-mouse IgG, A and M 
diluted 1/100 in 2% BSA in PBS and filtered 
through a 0.22/~m filter immediately prior to use, 
was added automatically by the instrument. The 
plates were incubated for 15 min at room temper- 
ature, and then the plates were subjected to 
vacuum within the instrument. The plates were 
then washed with 50 /~1 of PBS/well  and read in 
the fluorimeter in the instrument at the FITC 
settings (489/515 nm). 
Results 
Optimization of the fluorescent assay 
First evaluated was the ability to use the assay 
with whole cells to determine whether the vacuum 
used by the instrument (which can be selected as 
high or low) would allow the cells to remain intact 
and viable. To evaluate this property, cells were 
stained with fluorescein diacetate (FDA). These 
cells will retain the FDA if they remain intact and 
viable (Rotman and Papermaster, 1966). However, 
once the cells dry, the FDA may leak if the cells 
are washed again (Jones and Senft, 1985). Several 
experiments were performed with different cell 
lines. If the assay is performed without beads, the 
viability drops significantly (data not shown). Also, 
the vacuum is considerably less effective if the 
beads are not used. The fluorimeter is not accurate 
if the wells are not completely dry, so the inability 
to completely evacuate the wells in the absence of 
the beads is a significant drawback. Occasionally 
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Fig. 1. SAF assay performed using HTB 63 human melanoma 
cells and anti-melanoma monoclonal antibody 225.28s, with 
and without beads. Specific reactivity is shown by solid bars 
and background (reaction without cells) is shown by shaded 
bars. 
wells would not empty entirely even when beads 
were used. This problem occurred sporadically 
and may be a quality control problem with the 
plates. The assay is more sensitive in the presence 
of the beads, as shown in Fig. 1. The assay per- 
formed with the beads gives a much higher read- 
ing, although the background is also somewhat 
higher. We have found that use of the beads 
results in greater sensitivity and reproducibility. 
All of the rest of the results shown are with beads. 
Other parameters evaluated with the assay were: 
use of several washes (no difference with one 
compared to two or three); and different volumes 
of washes (no difference between 20 #1 compared 
to 50 ~1). Filtering the FITC-conjugated antibody 
was found to be very important in reducing back- 
ground fluorescence, possibly due to aggregates. 
However, blocking the plates with BSA prior to 
assay did not reduce non-specific sticking or fluo- 
rescence background, in contrast to the effect of 
pre-blocking in the DRIB assay (Stya et al., 1984). 
Comparison of DRIB and SAF 
The SAF assay was compared using similar 
reagents to the DRIB and the results are shown in 
Fig. 2. The assay was performed with HTB 77 
(human ovarian cancer cells) as the target cells, 
and 5G6 and UPC-10 as the positive and negative 
control antibodies, respectively. In both assays, 
the background is evaluated both by using a nega- 
tive control antibody and by testing wells receiv- 
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Fig. 2. Comparison of SAF and DRIB assays with HTB 77 
human ovarian cancer cells, with anti-ovarian cancer mono- 
clonal antibody 5G6.4 (A and C) and non-specific (control) 
monoclonal antibody UPC-10 (B and D). Specific reactivity is 
shown by solid bars, and non-specific reactivity (background, 
reaction without cells present) by shaded bars. In A and B, B 
on the x-axis represents reactivity with cells but without 
primary antibody. 
i ng  all  r e a g e n t s  b u t  w i t h o u t  t a r g e t  cells. T h e  S A F  
a s s a y  is q u i t e  c o m p a r a b l e  to  t he  D R I B  b y  c o m -  
p a r i s o n  o f  fig. 2 A  a n d  2C.  T h e  S A F  a s say  m a y  in 
f ac t  b e  m o r e  s e n s i t i v e  a t  l o w e r  c o n c e n t r a t i o n s  of  
a n t i b o d y  ( b e l o w  0.3 t ~ g / m l ) .  T h e  S A F  a s say  d o e s  
h a v e  m o r e  b a c k g r o u n d  r e a c t i v i t y  t h a t  c a n  b e  seen  
in  b o t h  Figs .  2 A  a n d  2B .  T h e  l o w e r  ( b u t  still  
o b s e r v a b l e )  r e a c t i v i t y  w i t h  U P C - 1 0 ,  a b o v e  the  
b a c k g r o u n d  r e a d i n g  for  t h o s e  wells ,  i n d i c a t e s  t he  
b a c k g r o u n d  p r o b l e m  w i t h  the  assay.  T h i s  p r o b l e m  
is n o t  seen  w i t h  t he  D R I B  a s s a y  as s h o w n  in  Fig.  
TABLE I 
COMPARISON OF PROTOCOLS AND TIME REQUIRED 
FOR DRIB AND SAF ASSAYS 
DRIB Time SAF Time Auto- 
elapsed elapsed marion 
(min) (min) 
Block plate 
(2-12 h) 120 Add beads 5 
Dot on target 
cells 5 Add target cells 10 h 
Add test Add test 
antibody 5 antibody 5 h 
Incubate 15 Incubate 15 
Wash 4 × 15 Wash 1 × 8 ~' 
Add rabbit, Add FITC- 
anti-mouse IgG 5 labelled goat, 
anti-mouse IgG 5 ~' 
15 Incubate 15 





Wash 4 × 
Add 125I-SpA 
incubate 
Wash 6-8 × 











b Capable of automation, not routinely done. 
2D,  where ' tes t '  reactivity is less than the back- 
ground reactivity (clearly negative). Thus, the SAF 
assay needs to be evaluated not  only for back- 
ground reactivity but  also to be compared  to a 
baseline activity in media and buffer controls. In  
the DRIB,  we routinely use a response to back- 
g round  ratio of 5 as a cut-off  to determine which 
cells will be saved. With  the SAF assay, more 
interpretat ion is needed. 
Time evaluation 
Table I shows a side-by-side compar ison of  the 
D R I B  and SAF assays for steps, automation,  and 
time comparisons.  The SAF assay can be per- 
formed in less than 2 h with minimal operator  
involvement,  even with the manual  steps we per- 
form. The D R I B  assay requires significant techni- 
cian intervention at each step (except for incuba- 
tions), more  washing, longer development  time, 
and requires a min imum of 11 h to get results. 
Ascites evaluation 
Product ion of  antibodies in ascites over time 
should be checked periodically for good ant ibody 
activity, since ant ibody product ion  by the cells in 
the ascites may drop over time (Goding,  1980; 
Eshhar, 1985). In  testing ascites, we observed that 
the usual dilution used in the D R I B  (1 /100)  gave 
unacceptably  high background  in the SAF assay, 
but  that  dilution of 1 /1000  or greater resulted in 
good reactivity over background in the SAF (see 
Fig. 3) and can be used to evaluate an t ibody 











1 /1 O 1 /100  1 /1000  1 / 1 0 0 0 0  
ASCITES DILUTION 
Fig. 3. Ascites testing of 6g10 anti-small cell carcinoma mono- 
clonal antibody with NCI 69 small carcinoma cell. Specific 
reaction is shown by solid bars, and background (reaction 
without cells) is shown by shaded bars. 
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Discussion 
This paper reports the development and use of  
a fluorescence assay with whole live cells that can 
be automated.  The assay described here is similar 
to the 'Ce l l -FLISA '  assay (Okumura  et al., 1986), 
but  differs in the use of  the automat ing instrument 
and the use of membrane-bo t tomed  plates. As 
previously reported, the use of membrane-bo t tom 
plates provides ease of access for more effective 
washing (Glassy et al., 1983; Stya et al., 1984). 
The cells remain viable and intact through the 
first separation step, which is impor tant  in screen- 
ing selectively for antigens on the cell surface. 
Al though the use of the Pandex screen machine 
has been reported for particle assays (Jolly et al., 
1984; Mayus  et al., 1986), this is the first report of  
the use of this system with whole, viable target 
cells. 
The automat ion of this fluorescence assay re- 
sults in a test turn-around time and sensitivity 
comparable  to that reported for ELISA. In com- 
parison to the DRIB,  the SAF assay is signifi- 
cantly faster, and requires very little operator  in- 
volvement once the plate is set up. 
We have shown that the SAF assay is useful for 
screening of  hybridomas,  is sensitive, rapid, gives 
results comparable  to the DRIB,  can be used to 
moni tor  ant ibody product ion in ascites, and is 
automated.  The use of this assay results in a 
significant labor reduction in the screening and 
maintenance of hybridomas.  
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